MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
MAXCYTE, INC. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.2%
- Operating margin
- -134.6%
- Net margin
- -114.8%
- Return on equity, FY2025
- -23.6%
Financial strength
- Current ratio
- 12.26
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 152.0%
Valuation
- P/E ratio
- –
- Price to sales
- 4.47
- Price to book
- 0.87
- Dividend yield
- –